AMRX vs LENZ
AMRX: Amneal Pharmaceuticals is a diversified biopharma company providing a broad range of essential, affordable generic and specialty medicines, alongside pharmaceutical distribution services. LENZ: LENZ Therapeutics is a commercial-stage ophthalmic company that developed VIZZ, the first FDA-approved, once-daily aceclidine-based eye drop for the treatment of presbyopia.
Side-by-side fundamentals
| Metric | AMRX | LENZ | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.75 | $5.34 | |
| Market cap as of 2026-07-23 | $5.7B | $167M | |
| P/E as of 2026-07-23 | 46.42 | n/a | |
| PEG as of 2026-07-23 | 2.57 | -0.01 | LENZ lower |
| Net margin as of 2026-07-23 | +4.0% | -519.3% | AMRX higher |
| Gross margin as of 2026-07-23 | +38.7% | +97.8% | LENZ higher |
| Operating margin as of 2026-07-23 | +14.3% | -563.8% | AMRX higher |
| ROE as of 2026-07-23 | -34.9% | -37.6% | AMRX higher |
| ROA as of 2026-07-23 | +3.4% | -34.8% | AMRX higher |
| Debt / equity as of 2026-07-23 | 136.58 | 0.00 | LENZ lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +10.9% | n/a | |
| Beta as of 2026-07-23 | 1.26 | 2.07 | |
| 1-year return as of 2026-07-22 close | +123.0% | -84.6% | AMRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.